Researchers
have discovered a new target for leukemia treatment after their study revealed
that cancerous cells utilize vitamin B6. The development of a new drug that
could prove to be more effective than current treatments is underway.
Leukemia
— a form of blood cancer that typically affects children and older adults — is
the tenth most common cancer in the
United States, representing 3.5% of all new cancer cases in the country.
According
to the National Cancer Institute, the disease is
also the fifth- highest cause of U.S. cancer deaths. Figures show an estimated
22,840 people died as a result of leukemia in 2019.
Acute
myeloid leukemia (AML) is the second most common form of the
disease. AML spreads quickly, leading to a comparatively low survival rate.
Less than one-third of people with AML survive for 5 years after being diagnosed.
AML’s
cancerous cells divide faster than the current treatment can kill them. Finding
a new therapy that better targets these cells is crucial for long-term
survival.
Cancer
cells use metabolism changes — where chemical reactions result in various cell
functions being switched on or sped up — to grow and spread at an abnormal
rate.
As
Lingbo Zhang, a fellow at the Cold Spring Harbor Laboratory (CSHL), NY, explains in a video: “One central feature of [a] leukemic
cell is that its metabolic processes have been reprogrammed to support abnormal
cell growth.”
A vitamin’s role
Zhang
and a team from both CSHL and Memorial Sloan Kettering Cancer Center (MSK), NY,
have now discovered how AML cell division happens so speedily. Surprisingly, it
revolves around a particular vitamin.
Vitamin
B6 is essential for the body to function normally. Derived solely from a
person’s diet, it helps with cell growth and metabolism, as well as producing neurotransmitters and red
blood cells.
Taking
genes from AML’s cancerous white blood cells, Zhang studied them to find more
than 230 separate genes that were “very
active in leukemic cells.”
The
team tested each one using CRISPR gene-editing technology to block the activity
of each gene. The authors published their findings in the Cancer Celljournal.
Used and abused by
cancer
The
scientists aimed to find a gene that halted the spread of the cancerous cells,
and they did: a gene that produces a metabolic enzyme called pyridoxal kinase
(PDXK).
PDXK
controls the usage of vitamin B6 by making proteins that, in turn,
produce the active form of the vitamin.
When
cells are healthy, they do not need vitamin B6 all the time. The enzyme
activates it when the time is right for cells to divide.
However,
the researchers found that in rapidly dividing cancerous cells, the enzyme
promoted this vitamin.
This
led to the proliferation of the AML cells, which could potentially lead to
further growth and spread of the disease.
“We have shown that this enzyme is essential for
leukemic cell growth,” Zhang says, explaining: “Leukemic cells are addicted to
vitamin B6. You can call it a vulnerability of the cancer.”
Scott
Lowe, co-author and chair of the Cancer Biology and Genetics Program at
MSK, adds: “We already knew that vitamin B6 served as a regulator for a whole
series of enzymes that are needed to make the building blocks required for cell
growth and proliferation.”
But,
he says, “this research suggested for the first time that the vitamin B6
pathway might be important for sustaining cancer.”
The
path to a more effective treatment
Most
importantly, this enzyme and vitamin combination could be a target for a new,
more effective form of therapy.
It
would not be as simple as reducing patients’ vitamin B6 intake because this may
affect vital functions throughout the body, including the brain and the rest of
the central nervous system.
Instead,
Zhang and his colleagues are working with medicinal chemists to develop a drug
that influences the PDXK enzyme.
By
doing this, leukemic cells would not be able to use vitamin B6 to their
advantage.
The
method might not only slow or halt the spread of leukemia, but it could also
avoid harming healthy cells that require vitamin B6 for survival.
Source:
Medical News Today
No comments:
Post a Comment